• AAPL 167.04
  • TSLA 149.9
  • AMZN 179.17
  • MSFT 404.33
  • INTC 35.04
  • EURUSD 1.0656
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. PINK /
  3. WUXIF.PINK

WuXi AppTec Co. Ltd (WUXIF PINK) stock market data APIs

$4.3501 0(0%) as of April 18, 2024

WuXi AppTec Co. Ltd Financial Data Overview

4.3501
4.3501
-
4.3501
4.3501
4.3501-12.6875
16 978 M
9.6669
387 M
40 341 M
0.1291
0.029
0.677
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'WUXIF',
Type: 'Common Stock',
Name: 'WuXi AppTec Co. Ltd',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00QXL3W50',
ISIN: NULL,
CUSIP: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Diagnostics & Research',
HomeCategory: NULL,
IsDelisted: false,
}

WuXi AppTec Co. Ltd Fundamental Data is available in our Financial Data APIs

  • Net Revenue 40 341 M
  • EBITDA 13 005 M
  • Earnings Per Share 0.45
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get WuXi AppTec Co. Ltd Earnings via APIs

  • Latest Release 2023-09-30
  • EPS/Forecast NaN

Get WuXi AppTec Co. Ltd End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get WuXi AppTec Co. Ltd latest news via APIs

Biotech trade association to split with China's WuXi AppTec

By Karen Freifeld (Reuters) - A Washington-based global trade association representing biotechnology companies is taking steps to "separate" from Chinese member Wuxi AppTec, according to a letter fro...

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma

AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval for a solid tumor cancer. PHILADELPHIA, Feb. 20, 2024 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ...
Do you have any questions?
support@eodhistoricaldata.com